Cross-Sector entity
World Health Organization is the most frequent co-covered peer, appearing in 5 of the 5 tracked stories. clinical-trial accounts for 2 of the 5 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each.
5 verified stories tracked
Last mentioned: Jul 23, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 60 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
World Health Organization is the most frequent co-covered peer, appearing in 5 of the 5 tracked stories. clinical-trial accounts for 2 of the 5 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each. 80% of these stories carry negative sentiment. We currently track 5 Cross-Sector stories that mention Africa Centres for Disease Control and Prevention, published between July 20, 2026 and July 23, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Africa Centres for Disease Control and Prevention. Shared-story counts are live from our verified record — not editorial picks.
First-in-Human Trial Begins
A Phase 1 clinical trial of the ChAdOx1-biEBOV vaccine, enrolling 50 healthy adults, commences with 4,000 doses supplied by the Serum Institute of India.
WHO sounds alarm
WHO reports that 80% of new cases are from unknown chains of transmission; striking workers agree to return if paid within 72 hours.
Health worker strike
Dozens of healthcare workers at an Ebola treatment centre in Bunia go on strike over unpaid salaries and bonuses.
Record outbreak data confirmed
Africa CDC reports the outbreak as the fastest-growing ever at 1,830 confirmed cases and 648 deaths. U.S. aid worker infection announced by CDC.
Clinical trials for treatments launched
Researchers initiate a highly anticipated clinical study to test experimental therapies against the Bundibugyo virus.
Kenya court suspends U.S.-backed facility
A Kenyan court order halts construction of a U.S.-planned quarantine facility for Americans exposed abroad, complicating evacuation plans.
WHO Declares Public Health Emergency
The World Health Organization declares the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), accelerating vaccine development and funding.
Ebola outbreak officially declared
Congolese authorities declare a fresh Ebola outbreak after weeks of undetected transmission, as later confirmed by WHO.
Outbreak identified
Congo detects an outbreak of the rare Bundibugyo Ebola virus in the eastern part of the country.
First U.S. doctor infected and evacuated
An American doctor working in Congo tests positive for Ebola and is transferred to Germany for treatment during the outbreak’s first week.
The record Ebola outbreak in Congo surpasses 1,830 cases and 648 deaths, with a second U.S. humanitarian worker now infected. The public health response faces severe funding and security obstacles, while experimental treatments enter clinical trials.
With no approved vaccine or treatment, the rare Bundibugyo ebolavirus driving the Congo outbreak has infected 1,830 people and killed 648. As two U.S. workers fall ill, recently launched clinical trials represent the only hope for a therapeutic breakthrough.
Source: wtvq.com
Congo’s overstretched health system is shown by 80% of new Ebola cases arising outside contact lists, a worker strike, and a $300M funding gap—highlighting the need for digital surveillance and workforce stability.
With 80% of new Ebola cases from unknown chains and the rare Bundibugyo strain lacking any approved vaccine or treatment, this outbreak exposes a critical gap in the biopharma pipeline and may catalyse urgent R&D investment.
A phase 1 trial of an adenovirus-vectored vaccine for the Bundibugyo Ebola strain is underway, enrolling 50 adults. With 620,000 doses pre-manufactured, the trial highlights rapid pandemic response but underscores immediate public health challenges as the outbreak’s death toll exceeds 700.
Source: deccanchronicle.com · seattletimes.com
